Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LIXT 
Lixte Biotechnology Holdings Inc (LIXT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: LIXT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70.27% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.97M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.37 | 52 Weeks Range 0.64 - 3.00 | Updated Date 06/30/2025 |
52 Weeks Range 0.64 - 3.00 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.45 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -81.14% | Return on Equity (TTM) -155.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4085448 | Price to Sales(TTM) - |
Enterprise Value 4085448 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.5 | Shares Outstanding 2756990 | Shares Floating 2527941 |
Shares Outstanding 2756990 | Shares Floating 2527941 | ||
Percent Insiders 18.43 | Percent Institutions 15.84 |
Upturn AI SWOT
Lixte Biotechnology Holdings Inc
Company Overview
History and Background
Lixte Biotechnology Holdings Inc. was founded in 2005. It is focused on discovering, developing, and commercializing novel small molecule therapeutics for cancer and other diseases. The company has been primarily focused on developing LB-100 series compounds.
Core Business Areas
- Drug Development: Lixte focuses on the discovery, development, and commercialization of small molecule therapeutics, specifically targeting protein phosphatase 2A (PP2A) inhibition.
Leadership and Structure
John S. Kovach, MD, serves as the CEO and Founder. The company has a board of directors responsible for oversight and strategic direction. It is structured around research and development.
Top Products and Market Share
Key Offerings
- LB-100 series: LB-100 series are the key offerings. These small molecules drugs are intended for cancer therapeutics by targeting protein phosphatase 2A (PP2A) inhibition. No significant market share or revenue data is publicly available for this developmental-stage product. Competitors include pharmaceutical companies developing other cancer therapies, such as those focusing on kinase inhibitors.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with a constant need for innovation. Cancer therapeutics is a significant market segment with high growth potential.
Positioning
Lixte is a small biotechnology company focused on a specific therapeutic approach (PP2A inhibition). Its competitive advantage lies in its novel technology. They're positioned as an early stage research company.
Total Addressable Market (TAM)
The global cancer therapeutics market is estimated to be billions of dollars. Lixte's positioning is early-stage development, so its current impact on TAM is minimal. The 2023 size of the cancer drugs market was $199.54 Billion and expected to hit $378.48 Billion by 2032.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (PP2A)
- Experienced leadership
- Early-stage development of proprietary molecules
Weaknesses
- Limited financial resources
- Dependence on LB-100 series
- High risk of clinical trial failure
- Small company size
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into other therapeutic areas
- Potential for orphan drug designation
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure of clinical trials
- Patent challenges
- Fund Raising
Competitors and Market Share
Key Competitors
- MRK
- PFE
- NVS
- BMY
- AZN
Competitive Landscape
Lixte faces intense competition from large pharmaceutical companies with greater resources and established market presence. Lixte's success hinges on its novel technology and successful clinical development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to being in the development phase.
Future Projections: Future growth depends on successful clinical trials and potential partnerships.
Recent Initiatives: Recent initiatives include advancing clinical trials of LB-100 series compounds.
Summary
Lixte Biotechnology is a small, high-risk, high-reward biotechnology company focusing on novel cancer therapies. Its strength lies in its unique approach to PP2A inhibition, but it faces challenges due to limited resources and intense competition. The company's future depends on successful clinical trials and potential partnerships. Investors should be aware of the inherent risks associated with early-stage pharmaceutical development.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Financial data is based on publicly available information and may not be exhaustive. Investment in Lixte Biotechnology Holdings Inc. involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lixte Biotechnology Holdings Inc
Exchange NASDAQ | Headquaters Pasadena, CA, United States | ||
IPO Launch date 2007-09-21 | CEO & Chairman Mr. Geordan G. Pursglove | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://lixte.com |
Full time employees 2 | Website https://lixte.com | ||
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.